Key result
Troglitazone linked to reduced carotid IMT vs control in type 2 diabetes.
Why the study?
Insulin resistance may be causally related to atherosclerosis, and the effect of troglitazone on carotid arterial wall thickness in type 2 diabetes was investigated.
Does troglitazone reduce common carotid arterial intimal and medial complex thickness in Japanese subjects with type 2 diabetes?
Cohort (n=135)
Does troglitazone reduce common carotid arterial intimal and medial complex thickness in Japanese subjects with type 2 diabetes?
Troglitazone significantly reduces carotid intima-media thickness in patients with type 2 diabetes, suggesting an inhibitory effect on early atherosclerotic progression.
Answers are grounded in this paper and cite their sources.
Troglitazone was associated with reduced carotid IMT in type 2 diabetes; leaves open whether insulin sensitization slows atherosclerosis, pending randomized confirmation.
ABTRACT There is increasing evidence that insulin resistance may be causally related to atherosclerosis. The measurement of common carotid arterial intimal and medial complex thickness (IMT) by B-mode ultrasound technique has been recognized as a powerful and non-invasive method to evaluate early atherosclerotic lesions. We investigated the effect of treatment with troglitazone, an insulin sensitizer, on IMT in a total of 135 Japanese subjects with type 2 diabetes. Troglitazone (400 mg daily) was administered for 6 months in 57 patients. Compared to control group (n = 78), the group given troglitazone showed a significant decrease in IMT as early as 3 months after the administration (IMT change: −0.080[se 0.016] mm vs. control 0.027[se 0.007] mm, P < 0.001). The decrease in IMT was also found after 6 months, although further decrease was not observed. Both HbA1c and postprandial serum triglycerides were decreased after troglitazone, but there was no statistically significant relation between a decrease in IMT and those in HbA1c or postprandial tri-glycerides. These findings indicate that troglitazone has a potent inhibitory effect on progression of early atherosclerotic lesions probably through the decreased insulin resistance in type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
J Minamikawa (1998) conducted a cohort in Type 2 diabetes (n=135). Troglitazone vs. Control group was evaluated on Change in common carotid arterial intimal and medial complex thickness (IMT) at 3 months (p=<0.001). Troglitazone decreased carotid arterial intimal and medial complex thickness compared to control in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: